360 High-Risk Vulnerability Immunization Tool V2.0 vs ClamAV: Side-by-Side Comparison (2026)
Features, pricing, ratings, and pros & cons — compared head-to-head.
360 High-Risk Vulnerability Immunization Tool V2.0 is a commercial endpoint protection platform tool by 360 Security Group (Qihoo 360). ClamAV is a free endpoint protection platform tool. Compare features, ratings, integrations, and community reviews side by side to find the best endpoint protection platform fit for your security stack.
CST VerdictBased on our analysis of NIST CSF 2.0 coverage, core features, company size fit, deployment model, here is our conclusion:
360 High-Risk Vulnerability Immunization Tool V2.0
Startups and SMBs with Windows-heavy infrastructure and patching backlogs should run 360 High-Risk Vulnerability Immunization Tool V2.0 first; it immunizes against the specific CVEs that drive ransomware campaigns (MS17-010, CVE-2019-0708) without requiring immediate OS updates. The tool supports Windows 7 through current versions and deploys on-premises, meaning air-gapped networks can actually use it. Skip this if you're looking for NIST PR.PS coverage beyond platform hardening,this tool stops known exploits, not supply chain attacks or firmware-level threats.
Teams running mail servers, file gateways, or hybrid Linux infrastructure will get the most value from ClamAV because its lightweight footprint and lack of licensing costs let you deploy detection everywhere without budget friction. The engine powers production mail filtering at scale across thousands of organizations, and integrates directly into tools like Postfix and Exim rather than requiring separate agent infrastructure. Skip this if you need behavioral detection, ransomware rollback, or endpoint response capabilities; ClamAV is signature-based detection only and won't catch novel malware or give you incident response tools.
